Evaluation of Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.1 for Postpartum Women

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-55
SponsorSamuel Lunenfeld Research Institute, Mount Sinai Hospital

About this trial

There is no widely used, statistically validated assessment for physical and mental health for the short- to medium-term in a postpartum population. PROMIS-29 has been validated for the assessment of these factors in a generic population, but has not been specifically evaluated for use with postpartum women.

This study is a longitudinal, single center observational cohort study designed to evaluate the reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.1 survey in a postpartum population. PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living. While this survey has shown utility in other populations, it has yet to be assessed in an obstetric population. The investigators plan to recruit patients who are recently postpartum from vaginal or cesarean delivery to complete virtual surveys at defined time points (0, 2, 6, and 12 weeks after delivery). The investigators will subject survey data to statistical measures of validity and reliability comparing with contemporaneously collected surveys of established metrics for quality of life (WHOQoLBREF) and general (global) state of health (numerical rating score 1-100).

The hypothesis is that the PROMIS-29 v2.1 questionnaire is a statistically valid and reliable means of assessing physical and mental health in a postpartum population.

Eligibility criteria

Qualifiers

18 years old and over

singleton births

37 or more weeks gestational age

multiparous or nulliparous patients

Disqualifiers

refusal to take part

are unable to give or have withdrawn consent

patients unable to communicate fluently in English

patients who are less than 18 years old

Trial design

Treatments tested in this trial

  • PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)
  • WHOQoLBREF (World Health Organization Quality of Life Brief Version)
  • EQ-5D-3L1 (not an acronym)

Treatment groups

200 Participants
are divided into 2 treatment groups